At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 272 enrolled
Drug / intervention
Tivozanib (AV-951) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Tivozanib (AV-951) and Placebo comparator for Carcinoma, Renal Cell. Completed, enrolled 272 participants across 26 sites in 3 countries.
Detailed Summary
This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesIndia, Russia, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartOct 2007
Primary CompletionAug 2010
TodayJul 2026
First PostedJul 17, 2007
Enrollment StartOct 1, 2007
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.0 years ago
Interventions
Tivozanib (AV-951)drug
solid oral dosage form taken daily for three weeks per one month cycle
Placebo comparatordrug
solid oral capsule containing excipients dosed daily for three weeks per month